Thermo Fisher Scientific's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 76.65.
Thermo Fisher Scientific's Days Inventory for the
three
months ended in Mar. 2026 was 77.41.
Thermo Fisher Scientific's Days Payable for the
three
months ended in Mar. 2026 was 49.42.
Therefore, Thermo Fisher Scientific's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 104.64.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thermo Fisher Scientific Cash Conversion Cycle Related Terms
Thermo Fisher Scientific Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Thermo Fisher Scientific's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:TMOS34 vs DHR, IDXX, A: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Thermo Fisher Scientific's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a Cash Conversion Cycle of 104.64 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Cash Conversion Cycle too high?
Thermo Fisher Scientific's current Cash Conversion Cycle is 104.64. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 73.46. Thermo Fisher Scientific's value of 104.64 is 42.5% above this industry median. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Cash Conversion Cycle compare to DHR and IDXX?
Thermo Fisher Scientific's Cash Conversion Cycle of 104.64 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 73.46. Thermo Fisher Scientific's value of 104.64 is 42.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 73.46, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Cash Conversion Cycle of 104.64 is 42.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 73.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Cash Conversion Cycle is 104.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$62.34, compared to a current price of R$54.84 — trading 12% below its estimated fair value. The current Cash Conversion Cycle is 104.64 and 42.5% above the Medical Diagnostics & Research industry median of 73.46. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Cash Conversion Cycle is 104.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$54.84 is trading 12% below its estimated GF Value™ of R$62.34.
GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.
Key valuation signals for BSP:TMOS34:
Cash Conversion Cycle: 104.64
GF Value™: R$62.34 vs. price of R$54.84 (12% below fair value)
Industry Position: 42.5% above the Medical Diagnostics & Research median
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
